BRISTOL-MYERS SQUIBB COMPANY Increase (Decrease) in Other Accrued Liabilities
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Increase (Decrease) in Other Accrued Liabilities of -$3.13 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in other accrued liabilities for the quarter ending 2026-06-30 was $360.00M, a 59.14% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in other accrued liabilities for the quarter ending 2026-03-31 was -$3.50B.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in other accrued liabilities for the quarter ending 2025-12-31 was -$2.40B.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in other accrued liabilities for the quarter ending 2025-09-30 was $1.70B, a 6.38% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in other accrued liabilities for fiscal 2025 was -$441.00M, a 129.72% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in other accrued liabilities for fiscal 2024 was $1.48B, a 64.16% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in other accrued liabilities for fiscal 2023 was $904.00M, a 111.71% increase from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in other accrued liabilities for fiscal 2022 was $427.00M, a 50.52% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $360.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$3.13B 10-Q · filed 2026-07-30 | -$5.53B derived: sum of 3 quarters · filed 2026-07-30 | -$3.83B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$3.50B 10-Q · filed 2026-04-30 | -$5.89B derived: sum of 2 quarters · filed 2026-04-30 | -$4.19B derived: sum of 3 quarters · filed 2026-04-30 | -$3.31B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$2.40B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$695.00M derived: sum of 2 quarters · filed 2026-02-11 | $186.00M derived: sum of 3 quarters · filed 2026-07-30 | -$441.00M 10-K · filed 2026-02-11 |
| 2025-09-30 | $1.70B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.58B derived: sum of 2 quarters · filed 2026-07-30 | $1.96B 10-Q · filed 2025-10-30 | $1.55B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $881.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $254.00M 10-Q · filed 2026-07-30 | -$151.00M derived: sum of 3 quarters · filed 2026-07-30 | $1.67B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$627.00M 10-Q · filed 2026-04-30 | -$1.03B derived: sum of 2 quarters · filed 2026-04-30 | $787.00M derived: sum of 3 quarters · filed 2026-04-30 | $1.52B derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$405.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.41B derived: sum of 2 quarters · filed 2026-02-11 | $2.15B derived: sum of 3 quarters · filed 2026-02-11 | $1.48B 10-K · filed 2026-02-11 |
| 2024-09-30 | $1.82B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.55B derived: sum of 2 quarters · filed 2025-10-30 | $1.89B 10-Q · filed 2025-10-30 | $1.68B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $735.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $70.00M 10-Q · filed 2025-07-31 | -$141.00M derived: sum of 3 quarters · filed 2026-02-11 | $1.39B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$665.00M 10-Q · filed 2025-04-24 | -$876.00M derived: sum of 2 quarters · filed 2026-02-11 | $657.00M derived: sum of 3 quarters · filed 2026-02-11 | $1.15B derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | -$211.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.32B derived: sum of 2 quarters · filed 2026-02-11 | $1.81B derived: sum of 3 quarters · filed 2026-02-11 | $904.00M 10-K · filed 2026-02-11 |
| 2023-09-30 | $1.53B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.02B derived: sum of 2 quarters · filed 2024-10-31 | $1.11B 10-Q · filed 2024-10-31 | $812.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $492.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-26 | -$418.00M 10-Q · filed 2024-07-26 | -$721.00M derived: sum of 3 quarters · filed 2025-02-12 | $419.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | -$910.00M 10-Q · filed 2024-04-25 | -$1.21B derived: sum of 2 quarters · filed 2025-02-12 | -$73.00M derived: sum of 3 quarters · filed 2025-02-12 | $447.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$303.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $837.00M derived: sum of 2 quarters · filed 2025-02-12 | $1.36B derived: sum of 3 quarters · filed 2025-02-12 | $427.00M 10-K · filed 2025-02-12 |
| 2022-09-30 | $1.14B derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $1.66B derived: sum of 2 quarters · filed 2023-10-26 | $730.00M 10-Q · filed 2023-10-26 | $691.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $520.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-27 | -$410.00M 10-Q · filed 2023-07-27 | -$449.00M derived: sum of 3 quarters · filed 2024-02-13 | $459.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | -$930.00M 10-Q · filed 2023-04-27 | -$969.00M derived: sum of 2 quarters · filed 2024-02-13 | -$61.00M derived: sum of 3 quarters · filed 2024-02-13 | $154.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | -$39.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $869.00M derived: sum of 2 quarters · filed 2024-02-13 | $1.08B derived: sum of 3 quarters · filed 2024-02-13 | $863.00M 10-K · filed 2024-02-13 |
| 2021-09-30 | $908.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $1.12B derived: sum of 2 quarters · filed 2022-10-26 | $902.00M 10-Q · filed 2022-10-26 | |
| 2021-06-30 | $215.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | -$6.00M 10-Q · filed 2022-07-27 | ||
| 2021-03-31 | -$221.00M 10-Q · filed 2022-04-29 | |||
| 2020-12-31 | $1.19B 10-K · filed 2023-02-14 | |||
| 2019-12-31 | $591.00M 10-K · filed 2022-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |